Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: Mechanisms of COX-2 inhibitor risk to heart disease
- 1 January 2011
- journal article
- Published by Elsevier BV in Life Sciences
- Vol. 88 (1-2), 24-30
- https://doi.org/10.1016/j.lfs.2010.10.017
Abstract
No abstract availableKeywords
Funding Information
- the National Institutes of Health (HL56712, HL79389, HL100807)
- American Heart Association (10GRNT4470042, T5 DK007676)
This publication has 20 references indexed in Scilit:
- Large-scale expression, purification, and characterization of an engineered prostacyclin-synthesizing enzyme with therapeutic potentialArchives of Biochemistry and Biophysics, 2008
- An active triple‐catalytic hybrid enzyme engineered by linking cyclo‐oxygenase isoform‐1 to prostacyclin synthase that can constantly biosynthesize prostacyclin, the vascular protectorThe FEBS Journal, 2008
- Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and RisksCurrent Pharmaceutical Design, 2007
- Engineering of a Protein with Cyclooxygenase and Prostacyclin Synthase Activities That Converts Arachidonic Acid to ProstacyclinBiochemistry, 2006
- Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical DesignsCurrent Pharmaceutical Design, 2006
- From the Design to the Clinical Application of Thromboxane ModulatorsCurrent Pharmaceutical Design, 2006
- Regulation of cyclooxygenase catalysis by hydroperoxidesBiochemical and Biophysical Research Communications, 2005
- The N-terminal membrane anchor domain of the membrane-bound prostacyclin synthase involved in the substrate presentation of the coupling reaction with cyclooxygenaseArchives of Biochemistry and Biophysics, 2005
- Prostaglandins and Leukotrienes: Advances in Eicosanoid BiologyScience, 2001
- Thromboxane biosynthesis in cardiovascular diseases.1990